The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM

At the Fraunhofer Institute For Toxicology And Experimental Medicine ITEM in Hanover, the clinical trial portfolio is centered on respiratory tract diseases, with a strong focus on conditions that affect breathing and lung function. Research here explores new approaches for asthma, chronic obstructive pulmonary disease, and related airway disorders, aiming to improve treatment options and better understand how therapies perform in people with chronic respiratory illness.

• Studies in asthma, including mild, mild to moderate, and allergic forms, to evaluate new treatment options and support better symptom control
• Research in chronic obstructive pulmonary disease to assess how investigational therapies may improve lung and heart-lung function
• Trials in idiopathic pulmonary fibrosis focused on safety and tolerability in a serious progressive lung disease

The site’s work also includes testing the safety, tolerability, and overall performance of emerging respiratory therapies, making it a notable center for early clinical research in lung disease.

A major part of the clinical research at this site involves asthma, with studies spanning mild asthma, mild to moderate asthma, and allergic asthma. These trials are designed to help determine whether new therapies can improve breathing control, reduce symptoms, and offer better options for patients living with persistent airway inflammation.

• Evaluating new treatments for allergic asthma to understand their effectiveness and safety
• Assessing investigational therapies for mild asthma and mild to moderate asthma to support better disease management
• Comparing established and emerging inhaled therapies to see how well they work in everyday respiratory care

This research reflects a practical focus on improving treatment choices for people with common but often long-term airway diseases.

The site is also active in chronic obstructive pulmonary disease research, including studies in COPD that examine how new therapies may affect breathing, lung hyperinflation, and overall respiratory performance. The goal is to better understand treatment effectiveness in a disease that can significantly limit daily activity and quality of life.

• Testing therapies for COPD to evaluate effects on lung and heart function
• Exploring treatment approaches for patients with hyperinflation and impaired breathing mechanics
• Studying how inhaled medicines may improve symptom control in chronic lung disease

These trials support the development of more effective options for people living with advanced respiratory disease.

Beyond asthma and COPD, the Fraunhofer Institute For Toxicology And Experimental Medicine ITEM contributes to research in idiopathic pulmonary fibrosis and early-stage safety studies in healthy volunteers. This area of work focuses on understanding how new compounds behave in the body while also checking their safety and tolerability in people.

• Safety and tolerability research in idiopathic pulmonary fibrosis to support future treatment development
• Early clinical testing in healthy volunteers to assess how new respiratory therapies are handled by the body
• Studies designed to generate first insights into the potential of new compounds for lung disease

This combination of disease-focused and early clinical research helps advance promising therapies from laboratory science toward practical respiratory care.